Aminoimidazo[1,2-a]pyridine Bearing Different Pyrazole Moieties as the Structural Scaffold for the Development of BACE1 Inhibitor; Synthesis, Structural Characterization, in vitro and in silico Studies

Curr Org Synth. 2022 Aug 6;19(6):685-692. doi: 10.2174/1570179419666220126113014.

Abstract

Regarding the critical role of amyloid-β plaques in the pathogenesis of Alzheimer's disease, a series of aminoimidazo[1,2-a]pyridine derivatives were designed and synthesized as potential anti-BACE1 agents targeting the production of amyloid-β plaques. In vitro biological results demonstrated that compounds 7b and 7f exhibited the best inhibitory potency against BACE1 with IC50 values of 22.48 ± 2.06 and 30.61 ± 3.48 μM, respectively. Also, the ligandprotein docking evaluations revealed that compounds 7b and 7f could effectively bind with the different pockets of BACE1 through different interactions with the residue of the active site. The results of current studies underline the potential role of aminoimidazo[1,2-a] pyridine-containing pyrazole derivatives for developing novel BACE1 inhibitors.

Keywords: 2-a]pyridine; Alzheimer’s disease; Aminoimidazo[1; BACE1 inhibitor; docking; pyrazole; synthesis.

Publication types

  • Letter

MeSH terms

  • Amyloid Precursor Protein Secretases* / chemistry
  • Amyloid Precursor Protein Secretases* / metabolism
  • Amyloid beta-Peptides / metabolism
  • Aspartic Acid Endopeptidases* / chemistry
  • Aspartic Acid Endopeptidases* / metabolism
  • Pyrazoles / pharmacology
  • Pyridines / pharmacology

Substances

  • Amyloid beta-Peptides
  • Pyrazoles
  • Pyridines
  • Amyloid Precursor Protein Secretases
  • Aspartic Acid Endopeptidases